Sensitization Study of ATx201 in Healthy Volunteers

UNION Therapeutics

Status and phase

Completed

Phase 1

Conditions

Sensitivity, Contact

Treatments

Drug: ATx201 Placebo Gel

Drug: ATx201

Study type

Interventional

Funder types

Industry

Identifiers

NCT03375957

ATx201-005

Details and patient eligibility

About

This is a Phase I, single-site study to evaluate the sensitization potential of topically applied ATx201 GEL, 2% and 4%, along with a placebo control, in healthy human subjects.

Enrollment

240 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Good general health
Body Mass Index no less than 19.0 and no greater than 36.0 kg/m² (inclusive).
Demonstrates a Fitzpatrick skin score of I - IV
Female subjects must agree to use acceptable contraceptive methods from the Screening Visit through 90 days after the End of Study (EOS) Visit; or postmenopausal status with no menses for at least 1 year prior to the Screening Visit.
Willing to refrain from excessive consumption of sodium in food or beverage 48 hours prior to Day 1 through EOS Visit.
Willing to shower using the same non-medicated soap/cleansers, and abstain from excessive sun exposure (including tanning salons) from the Screening Visit through EOS Visit.

Exclusion criteria

Reports a history of diabetes mellitus, clinically significant asthma (acceptable if no episode within 5 years prior to Day 1), or currently diagnosed with hypertension or circulatory disease.
Reports use of any oral, nasal or topical corticosteroids, or oral or topical retinoids (other than Vitamin A at normal dietary amounts)
Reports a significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
Reports a history of significant skin conditions or disorders such as psoriasis, atopic dermatitis, etc.
Reports a history of significant dermatologic cancers.
Displays an obvious difference in skin color between upper arms or upper back or the presence of a skin anomaly
Reports smoking or use of tobacco or nicotine delivery products within 14 days prior to Day 1 through EOS Visit.
Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator.
A female who is pregnant, lactating, breastfeeding, or intends to become pregnant over the course of the study.
Reports a history of drug or alcohol addiction or abuse within the past year.
Reports having donated blood or plasma within 48 hours prior to Day 1 through EOS Visit.
Subject exhibits excessive hair density on the upper arms or back such that patch adhesion could be compromised.
Subject reports undergoing hair depilation (e.g. chemical, laser, physical) within 30 days prior to Day 1 through EOS Visit.